Biohaven gets Q1 2027 FDA review goal for Vyglxia

The assigned first-quarter 2027 goal date is not a commitment to act by then or approve the application.

Rhea-AI Filing Summary

Biohaven Ltd. said the FDA accepted for review its resubmitted new drug application for Vyglxia (troriluzole) for SCA. The resubmission included new positive supportive analyses, and the FDA considers it a complete response to the November 4, 2025 action letter. The agency assigned a user fee goal date in the first quarter of 2027 and plans to convene its Peripheral and Central Nervous System Advisory Committee to obtain input from external stakeholders; the anticipated meeting date will be forthcoming in the near term.

The goal date does not assure FDA action by then or approval. Troriluzole is an investigational drug and has not been approved for any indication in the United States.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

FDA user fee goal date: First quarter of 2027 FDA action letter date: November 4, 2025

2 metrics

FDA user fee goal date First quarter of 2027 Assigned for review of the resubmitted application

FDA action letter date November 4, 2025 The resubmission is considered a complete response to this action letter

Key Terms

new drug application, complete response, user fee goal date, investigational drug

4 terms

new drug application regulatory

"new drug application resubmission for Vyglxia"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

complete response regulatory

"a complete response to the November 4, 2025 action letter"

A complete response is a positive outcome in which a company’s efforts to address issues or questions fully resolve the problem, often meaning that no further action or investigation is needed. For investors, it signals that concerns have been thoroughly addressed, which can boost confidence in the company's stability or decision-making. Think of it like a doctor fully treating an illness, leaving no remaining symptoms.

user fee goal date regulatory

"assigned a user fee goal date"

investigational drug regulatory

"Troriluzole is an investigational drug"

An investigational drug is a medicine that is still being tested and has not yet received full regulatory approval for general use. Investors care because the drug’s success or failure in studies and regulatory reviews can dramatically change a company’s future revenue and value — similar to backing a prototype product that may or may not clear safety and effectiveness checks before reaching customers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the latest FDA update on BHVN's SCA application?

The FDA accepted Biohaven's resubmitted new drug application for Vyglxia (troriluzole) for SCA and considers the resubmission a complete response to its November 4, 2025 action letter. The resubmission included new positive supportive analyses.

When is the FDA expected to act on BHVN's SCA application?

The FDA assigned a user fee goal date in the first quarter of 2027. The goal does not assure that the FDA will act by then or approve the application.

Will an FDA advisory committee review BHVN's SCA application?

The FDA plans to convene its Peripheral and Central Nervous System Advisory Committee to obtain input from external stakeholders. The anticipated date of the meeting will be forthcoming in the near term.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/22/2026 - 07:00 AM EDT Accepted by SEC EDGAR 10/22/2026 - 07:00 AM EDT Learn about SEC filing dates

0001935979false00019359792026-10-222026-10-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2026

Biohaven Ltd.

(Exact name of registrant as specified in its charter)

British Virgin Islands			001-41477			Not applicable
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

c/o Biohaven Pharmaceuticals, Inc.

215 Church Street

New Haven, Connecticut 06510

(Address of principal executive offices, including zip code)

(203) 404-0410

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol			Name of each exchange on which registered
Common Shares, no par value			BHVN			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 7.01    Regulation FD Disclosure.

On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program.

The FDA has informed Biohaven that the company’s new drug application resubmission for Vyglxia (troriluzole) in SCA has been accepted for review. The resubmission included new positive supportive analyses.

The FDA communicated that it considers the resubmission a complete response to the November 4, 2025 action letter, and has assigned a user fee goal date in the first quarter of 2027. The FDA plans to convene a meeting of the Peripheral and Central Nervous System Advisory Committee to obtain input from external stakeholders. The anticipated date of the advisory committee meeting will be forthcoming in the near term.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the FDA's review of the troriluzole NDA resubmission, the PDUFA target goal date and the potential for approval. The PDUFA target action date is a goal and does not assure that the FDA will act by that date or approve the NDA. The FDA may extend the review period, including if it determines that information submitted during the review constitutes a major amendment, may request additional information, or may issue a complete response letter. Troriluzole is an investigational drug and has not been approved for any indication in the United States.

These statements are subject to risks and uncertainties, including those described in Exhibit 99.1 and under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, that could cause actual results to differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Exhibit Description
104						The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 22, 2026

Biohaven Ltd.
By:			/s/ Matthew Buten
			Matthew Buten
			Chief Financial Officer

3

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB